Literature DB >> 20117403

Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction.

Robin A P Weir1, Ashley M Miller, Grace E J Murphy, Suzanne Clements, Tracey Steedman, John M C Connell, Iain B McInnes, Henry J Dargie, John J V McMurray.   

Abstract

OBJECTIVES: This study sought to assess, for the first time, the relationship between serum concentrations of the soluble interleukin-1 receptor family member ST2 (sST2) and serial change in left ventricular (LV) function after acute myocardial infarction (AMI).
BACKGROUND: Serum sST2 levels are elevated early after AMI and are associated with lower pre-discharge LV ejection fraction and adverse cardiovascular outcomes.
METHODS: The sST2 levels were measured in 100 patients (mean age 58.9 +/- 12.0 years; 77% male), admitted with AMI with resultant LV systolic dysfunction, at baseline and at 12 and 24 weeks. Patients underwent cardiac magnetic resonance imaging and measurement of N-terminal pro-brain natriuretic peptide, norepinephrine, and aldosterone at each time point.
RESULTS: Median sST2 decreased from 263.3 pg/ml at baseline to 140.0 pg/ml at 24 weeks (p < 0.001). Serum sST2 correlated significantly with LV ejection fraction at baseline (r = -0.30, p = 0.002) and 24 weeks (r = -0.23, p = 0.026); change in sST2 correlated with change in LV end-diastolic volume index (r = -0.24, p = 0.023). Level of sST2 was positively associated with infarct volume index at baseline (r = 0.26, p = 0.005) and 24 weeks (r = 0.22, p = 0.037), and with change in infarct volume index (r = -0.28, p = 0.001). Level of sST2 was significantly higher in patients with greater infarct transmurality and endocardial extent, and in the presence of microvascular obstruction. Level of sST2 correlated significantly with norepinephrine and aldosterone, but not with N-terminal pro-brain natriuretic peptide.
CONCLUSIONS: Measurement of sST2 early after AMI assists in the prediction of medium-term LV functional recovery. Novel relationships were observed between sST2, infarct magnitude/evolution, and aldosterone. Serum sST2 may be of pathophysiological importance in ventricular and infarct remodeling after AMI. (Effects of Eplerenone on Left Ventricular Remodelling Following Heart Attack; NCT00132093). Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20117403     DOI: 10.1016/j.jacc.2009.08.047

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  79 in total

Review 1.  Myocardial remodeling, an overview.

Authors:  Dennis V Cokkinos; Costas Pantos
Journal:  Heart Fail Rev       Date:  2011-01       Impact factor: 4.214

2.  A carbon nanotube toxicity paradigm driven by mast cells and the IL-₃₃/ST₂ axis.

Authors:  Pranita Katwa; Xiaojia Wang; Rakhee N Urankar; Ramakrishna Podila; Susana C Hilderbrand; Robert B Fick; Apparao M Rao; Pu Chun Ke; Christopher J Wingard; Jared M Brown
Journal:  Small       Date:  2012-07-06       Impact factor: 13.281

Review 3.  Reverse Cardiac Remodeling and ARNI Therapy.

Authors:  Andrew Abboud; James L Januzzi
Journal:  Curr Heart Fail Rep       Date:  2021-01-22

Review 4.  IL-33/ST2 Axis in Organ Fibrosis.

Authors:  Ourania S Kotsiou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Front Immunol       Date:  2018-10-24       Impact factor: 7.561

Review 5.  Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure.

Authors:  Shweta R Motiwala; Hanna K Gaggin
Journal:  Curr Heart Fail Rep       Date:  2016-10

Review 6.  ST2 as a cardiovascular risk biomarker: from the bench to the bedside.

Authors:  James L Januzzi
Journal:  J Cardiovasc Transl Res       Date:  2013-04-05       Impact factor: 4.132

Review 7.  Circulating biomarkers in the early detection of hypertensive heart disease: usefulness in the developing world.

Authors:  Dike Ojji; Elena Libhaber; Kim Lamont; Friedrich Thienemann; Karen Sliwa
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

8.  Biomarker Guided Therapy in Chronic Heart Failure.

Authors:  Hans-Peter Brunner-La Rocca; Sema Bektas
Journal:  Card Fail Rev       Date:  2015-10

9.  Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study.

Authors:  Erin E Coglianese; Martin G Larson; Ramachandran S Vasan; Jennifer E Ho; Anahita Ghorbani; Elizabeth L McCabe; Susan Cheng; Michael G Fradley; Dana Kretschman; Wei Gao; George O'Connor; Thomas J Wang; James L Januzzi
Journal:  Clin Chem       Date:  2012-10-11       Impact factor: 8.327

10.  Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality.

Authors:  Jiri Parenica; Jan Malaska; Jiri Jarkovsky; Jolana Lipkova; Milan Dastych; Katerina Helanova; Jiri Litzman; Josef Tomandl; Simona Littnerova; Jana Sevcikova; Roman Gal; Pavel Sevcik; Jindrich Spinar; Monika Pavkova Goldbergova
Journal:  Exp Clin Cardiol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.